{"id":"n_crarqscwsr6gna36mcia","seq":9664850,"kind":"article","title":"“시력 줄어들 위험 있다” 식약처, GLP-1 비만치료제 안전성 서한 배포","title_en":"Food and Drug Administration distributes letter on safety of GLP-1 obesity treatment","url":"https://kormedi.com/2902989","summary":"비만치료에 사용되는 글루카곤유사펩타이드-1(GLP-1) 계열 의약품의 시력 저하 부작용이 꾸준히 지적되면서, 국내 식품의약품안전처도 안전조치를 추진하기로 결정했다. 식약처는 의약 전문가와… The post “시력 줄어들 위험 있다” 식약처, GLP-1 비만치료제 안전성 서한 배포 appeared first on 코메디닷컴 .","published":"2026-11-11T00:51:08Z","seen":"2026-11-11T00:54:02Z","lang":"ko","country":"KR","source":{"id":"kite-kormedi-com-1cc5b2","name":"kormedi.com","domain":"kormedi.com"},"via":"kite-kormedi-com-1cc5b2","topics":["medicine","바이오·제약","의료","glp-1","마운자로","비만약","비만치료제","에페"],"authors":["장자원 기자"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"image":"https://kormedi.com/wp-content/uploads/2026/11/2026-11-11-93752-edited.png","story":"st_s7hy467hhfdgv77aaklq","category":"health","category_p":0.89,"sentiment":"negative","tone":-0.56,"political":0.2}